Literature DB >> 8176925

Adrenal adenocarcinoma: a review of 53 cases.

G C Zografos1, D L Driscoll, C P Karakousis, R P Huben.   

Abstract

PROBLEM: Fifty-three patients (30 men, 23 women) with histologically proven adrenal carcinoma were reviewed. Nineteen (36%) had endocrine manifestations from functioning tumors. Arteriography was positive in 95% (19/20), CT scan in 94% (17/18), and ultrasound in 92% (12/13). Seventy-six percent of the patients, at the time of diagnosis, were stage III and IV. Most common metastatic sites were the liver, lymph nodes, bone, and lungs. Local recurrence developed in 39% of cases (15/38).
METHOD: Forty-one patients underwent an operation. Complete surgical removal of all gross tumor was achieved in 24 patients. RESULT: The overall median survival time was 8 months, and the estimated 5-year survival rate 19%. There were significant differences in survival between the various stages (P = 0.01) and between the group of patients who underwent complete excision of the tumor and those with incomplete resection (P = 0.002).
CONCLUSIONS: Complete surgical excision offers the best prospect for long-term survival in localized adrenal carcinoma.

Entities:  

Mesh:

Year:  1994        PMID: 8176925     DOI: 10.1002/jso.2930550306

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  9 in total

Review 1.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

2.  Operative management for recurrent and metastatic adrenocortical carcinoma.

Authors:  Nicole M Datrice; Russell C Langan; R Taylor Ripley; Clinton D Kemp; Seth M Steinberg; Bradford J Wood; Steven K Libutti; Tito Fojo; David S Schrump; Itzhak Avital
Journal:  J Surg Oncol       Date:  2011-12-20       Impact factor: 3.454

Review 3.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

4.  Combined liver and inferior vena cava resection for adrenocortical carcinoma.

Authors:  Susumu Ohwada; Masaru Izumi; Yoshifumi Tanahashi; Susumu Kawate; Kunihiro Hamada; Hirofumi Tsutsumi; Jun Horiguchi; Yukio Koibuchi; Toru Takahashi; Masanobu Yamada
Journal:  Surg Today       Date:  2007-03-26       Impact factor: 2.549

Review 5.  Current and emerging therapies for advanced adrenocortical carcinoma.

Authors:  Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu
Journal:  Oncologist       Date:  2011-01-06

6.  Case studies in hypertension. Adrenal carcinoma.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Sep-Oct       Impact factor: 3.738

7.  Pure androgen-secreting adrenal adenoma associated with resistant hypertension.

Authors:  René Rodríguez-Gutiérrez; Mario Arturo Bautista-Medina; Ana Eugenia Teniente-Sanchez; Maria Azucena Zapata-Rivera; Juan Montes-Villarreal
Journal:  Case Rep Endocrinol       Date:  2013-05-29

Review 8.  Adrenal cortical carcinoma.

Authors:  R P Boushey; A P Dackiw
Journal:  Curr Treat Options Oncol       Date:  2001-08

Review 9.  Treatment of adrenocortical carcinoma: contemporary outcomes.

Authors:  David Y T Chen; R Ernest Sosa; Douglas S Scherr
Journal:  Curr Urol Rep       Date:  2004-02       Impact factor: 2.862

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.